ROCK1 and glaucoma: Here, the authors show that AAV-delivered CasRx to reduce the expression of Rock1 and Rock2 as well as Aqp1 and Adrb2 can significantly reduce intraocular pressure, ultimately delaying glaucoma progression in mice.